TMAO also can reduce the reverse cholesterol transport through activating the nuclear receptor Farnesoid X receptor (FXR) and small heterodimer partner (SHP) to inhibit the expression of Cyp7a1, which could reduce the synthesis of bile acids in the liver with the result of accelerating atherosclerosis development (89, 90). The gene discussed is NR0B2; the disease is atherosclerosis.